UNSPSC 51101912: Hydroxychloroquine

This classification denotes an antimalarial agent with the molecular formula C18H26ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4QWG6N8QKH, chemically known as ethanol, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)- but generally known as hydroxychloroquine, which bears US NIH Compound Identifier 3652. European Medicines Agency schedules Hydroxychloroquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08077MIG.

UNSPSC 51101912 Hydroxychloroquine is a Commodity code that nominally addresses a single pharmaceutical product, yet recent state and local solicitations tagged under it reveal a mismatch: the opportunities posted show procurement of emergency medical supplies, naloxone kits, generic pharmaceuticals, and over-the-counter products — not hydroxychloroquine specifically. State and local buyers posting under this code are acquiring medical and first aid consumables for emergency response, pharmacy benefit programs, and health agency operations. The issuing bodies include county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances. Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent postings.

Recent opportunities illustrate the actual scope of work. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, awarded on a fixed-fee basis with a two-year initial term and one-year renewal option. The City of Tampa issued IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies serving the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00, designated as a sheltered procurement for certified Small Local Business Enterprises with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager relationships. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with responses due March 26, 2026 and contract effectiveness July 1, 2026. The code shows limited relevant recent activity when matched to its nominal hydroxychloroquine scope; opportunities are broader pharmaceutical and medical supply procurements.